Symptoms persisting after hospitalisation for COVID-19: 12 months interim results of the CO-FLOW study

L. Martine Bek, Julia C. Berentschot, Majanka H. Heijenbrok-Kal, Susanne Huijts, Michel E. van Genderen, J. Hans Vlake, Jasper van Bommel, Joachim G.J.V. Aerts, Gerard M. Ribbers, Rita J.G. van den Berg-Emons, Merel E. Hellemons

Source: ERJ Open Res, 8 (4) 00355-2022; 10.1183/23120541.00355-2022
Journal Issue: October

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Abstract

Introduction

A large proportion of patients experience a wide range of sequelae after acute COVID-19, especially after severe illness. The long-term health sequelae need to be assessed. Our objective was to longitudinally assess persistence of symptoms and clusters of symptoms up to 12 months after hospitalisation for COVID-19 and to assess determinants of the main persistent symptoms.

Methods

In this multicenter prospective cohort study patients with COVID-19 are followed up for 2 years with measurements at 3, 6, 12 and 24 months after hospital discharge. Here, we present interim results regarding persistent symptoms up to 12 months.

Results

We included 492 patients; mean±sd age was 60.2±10.7 years, 335 (68.1%) were males, median length of hospital stay was 11 (6.0–27.0) days. At 3 months after discharge 97.0% of the patients had at least one persisting symptom, this declined to 95.5% and 92.0% at 6 and 12 months, respectively (p=0.010). Muscle weakness, exertional dyspnoea, fatigue, and memory and concentration problems were the most prevalent symptoms with rates over 50% during follow-up. Over time, muscle weakness, hair loss and exertional dyspnoea decreased significantly (p<0.001), while other symptoms such as fatigue, concentration and memory problems, anosmia and ageusia persisted. Symptoms from the physical and respiratory cluster declined significantly over time, in contrast to the fatigue and cognitive symptom clusters.

Conclusion

The majority of patients experienced COVID-19 sequelae up to 12 months after severe infection. Whereas physical and respiratory symptoms showed slow gradual decline, fatigue and cognitive symptoms did not evidently resolve over time.



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Martine Bek, Julia C. Berentschot, Majanka H. Heijenbrok-Kal, Susanne Huijts, Michel E. van Genderen, J. Hans Vlake, Jasper van Bommel, Joachim G.J.V. Aerts, Gerard M. Ribbers, Rita J.G. van den Berg-Emons, Merel E. Hellemons. Symptoms persisting after hospitalisation for COVID-19: 12 months interim results of the CO-FLOW study. ERJ Open Res, 8 (4) 00355-2022; 10.1183/23120541.00355-2022

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.